Back to results
US 8,278,297 B2Granted
Protein kinase inhibitors
AssigneeVertex Pharmaceuticals Incorporated
InventorsJean-Damien Charrier, Steven Durrant
Life of this patent
Estimating the term…
Abstract
In one aspect, the invention provides compounds of Formula I or pharmaceutically acceptable salts thereof. In another aspect, the invention provides methods for treatment of diseases or disorders mediated by a protein kinase, comprising administering a therapeutically effective amount of a compound of this invention.
Claims36
A compound of Formula I
- or a pharmaceutically acceptable salt thereof, wherein
- Y is O or NR9;
- R1 is aryl or 5-14 membered heteroaryl having 1-3 heteroatoms independently selected from N, O, or S, either of which is optionally substituted with 1-3 substituents independently selected from alkyl, halo, amino, alkoxy, haloalkyl, alkylsulfonyl, nitro, phenyl, piperazinyl, or alkylpiperazin-1-yl;
- R2 is H, alkyl, or cycloalkyl;
- each of R3 and R4 is independently H, alkyl, cycloalkyl, aryl, or 5-14 membered heteroaryl having 1-3 heteroatoms independently selected from N, O, or S;
- or R3 and R4, together with the carbon atom to which they are attached, form a cycloalkyl;
- each of R5 and R6 is independently H, alkyl, cycloalkyl, aryl, or 5-14 membered heteroaryl having 1-3 heteroatoms independently selected from N, O, or S;
- R7 is H, alkyl, cycloalkyl, aryl, 5-14 membered heteroaryl having 1-3 heteroatoms independently selected from N, O, or S, or 3-14 membered heterocyclyl having 1-3 heteroatoms independently selected from N, O, or S;
- R8 is alkyl optionally substituted with halo, —OH, or alkoxy;
- R9 is H or alkyl;
- or
- R2 and R9, together with the atoms to which they are attached, form a 5- to 8-membered monocyclic ring containing additional 0 to 2 heteroatoms each independently selected from O, N, and S, wherein said monocyclic ring is optionally substituted with 0 to 4 groups each independently being alkyl, halo, alkoxy, or hydroxy;
- and
- q is 0 or 1,
- Provided that when q is 0, then Y is NR9, and R2 and R9, together with the atoms to which they are attached, form a 5- to 8-membered monocyclic ring containing additional 0-2 hetero atoms each independently selected from O, N, and S, wherein said monocyclic ring is optionally substituted with 0 to 4 groups each independently being halo or alkyl.
12 more elements
Dependencies are inferred from the claim text.